Hisamori Kato

Yokohama, JP 
Yokohama, JP 

Overview

Hisamori Kato practices practicing medicine in Yokohama, Japan.

Their clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Cerebral Hypoxia, Salpingo-Oophorectomy, and Oophorectomy.

They are actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Locations

Yokohama, Japan
Other Locations
Hamamatsu, Japan
Kanagawa, Japan
Saitama, 3500495, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 24, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 2
View 1 Less Clinical Trial

43 Total Publications

Ameloblastoma Displays Primary Cilia Maintenance and CEP164 Overexpression.
Ameloblastoma Displays Primary Cilia Maintenance and CEP164 Overexpression.
Journal: Journal of dental research
Published: February 24, 2026

Frequently Asked Questions about Hisamori Kato

Is Hisamori Kato a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Hisamori Kato is classified as an Experienced expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hisamori Kato participate in research or clinical trials?

Yes. Hisamori Kato has published 43 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Hisamori Kato's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kato's expertise for a condition
ConditionClose
        View All 13 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile